Ponezumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | beta-amyloid |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6552H10158N1730O2090S52 |
Molar mass | 148272.48 g·mol−1 |
(what is this?) (verify) |
Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.[1][2]
Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.[3]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
- ^ Popescu CD, Trofin D, Ignat B, Matei D (2014). "New Aspects of Therapeutic Management in Alzheimer`s Disease". In Atta-ur-Rahman (ed.). Frontiers in Clinical Drug Research: Alzheimer Disorders. Vol. 3. Sharjah: Bentham Science Publishers. p. 55. doi:10.2174/9781681080680115030004. ISBN 978-1-68108-068-0.
- ^ "Alzforum".
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs that are a monoclonal antibody
- Drugs developed by Pfizer
- Anti-amyloid monoclonal antibodies
- Experimental monoclonal antibodies
- All stub articles
- Monoclonal antibody stubs
- Nervous system drug stubs